Elvia Cowan Sells 11,623 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) SVP Elvia Cowan sold 11,623 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total transaction of $556,974.16. Following the sale, the senior vice president owned 14,534 shares in the company, valued at $696,469.28. The trade was a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Vaxcyte Stock Down 2.5%

Shares of Vaxcyte stock opened at $45.41 on Wednesday. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $93.77. The company has a market capitalization of $5.94 billion, a P/E ratio of -9.38 and a beta of 1.28. The company has a 50 day moving average of $45.63 and a 200 day moving average of $38.48.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same quarter last year, the business posted ($0.83) EPS. As a group, research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. HighVista Strategies LLC lifted its stake in Vaxcyte by 1.1% in the second quarter. HighVista Strategies LLC now owns 33,457 shares of the company’s stock valued at $1,088,000 after buying an additional 355 shares during the last quarter. Arizona State Retirement System raised its position in Vaxcyte by 1.6% in the 3rd quarter. Arizona State Retirement System now owns 34,333 shares of the company’s stock valued at $1,237,000 after purchasing an additional 543 shares during the last quarter. Hsbc Holdings PLC raised its position in Vaxcyte by 3.1% in the 1st quarter. Hsbc Holdings PLC now owns 18,461 shares of the company’s stock valued at $675,000 after purchasing an additional 552 shares during the last quarter. J.Safra Asset Management Corp boosted its stake in Vaxcyte by 18.5% during the 2nd quarter. J.Safra Asset Management Corp now owns 3,746 shares of the company’s stock worth $122,000 after purchasing an additional 585 shares during the period. Finally, Atria Investments Inc grew its position in Vaxcyte by 11.1% during the 2nd quarter. Atria Investments Inc now owns 6,816 shares of the company’s stock worth $222,000 after purchasing an additional 683 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PCVX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price target for the company. BTIG Research reiterated a “buy” rating and issued a $85.00 price target on shares of Vaxcyte in a research note on Monday, November 10th. Finally, Leerink Partners set a $77.00 price objective on shares of Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $97.83.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.